BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 24, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Oncophage vitespen: Additional Phase I/II data

Additional data from 32 evaluable patients with recurrent high-grade glioma in an open-label, U.S. Phase I/II trial showed that Oncophage resulted in an overall median survival of 44 weeks following tumor resection. Additionally, 70% and 41% of patients survived >36 weeks and >=1 year, respectively. Oncophage was well...

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >